ICH Quality Guideline · Manufacturing Comparability

ICH Q5E: Comparability of Biotechnological/Biological Products

Q: Are release specifications enough to demonstrate comparability?

No. Specifications alone are generally inadequate because they are designed for routine quality control rather than comprehensive product characterisation.

ICH Q5E provides the harmonised framework for assessing whether a biotechnology or biological product remains comparable after a manufacturing-process change. The current Step 4 version, dated 18 November 2004, focuses primarily on quality evidence and is designed to help manufacturers demonstrate that a change has not adversely affected product quality, safety, or efficacy. The guideline recognises that manufacturing changes are normal throughout development and the commercial lifecycle—for example, scale-up, process improvement, equipment or facility changes, stability improvement, or adaptation to regulatory requirements. Q5E does not require pre-change and post-change material to be identical. Instead, the objective is to establish that they are highly similar and that any observed differences are sufficiently understood and are not expected to adversely affect safety or efficacy. The comparability exercise can rely on analytical testing and biological assays and, when quality data are not enough, may need nonclinical or clinical bridging studies. This article explains the Q5E framework, quality considerations, stability, process-control expectations, development-stage comparability, and the circumstances in which additional studies may be needed.

Featured-snippet definition: ICH Q5E is the ICH guideline for demonstrating that a biotechnology or biological product made after a manufacturing change is comparable to the pre-change product in quality, safety, and efficacy.

What Is ICH Q5E?

ICH Q5E is formally titled Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process. It reached Step 4 on 18 November 2004.

The guideline was developed to provide principles for comparing biotechnology and biological products before and after a manufacturing change. Its main emphasis is on quality data, while recognising that nonclinical or clinical information may sometimes be needed.

Q5E should be viewed alongside other relevant ICH Quality Guidelines, including those covering viral safety, expression constructs, stability, cell substrates, specifications, and analytical validation.

Objective of the ICH Q5E Comparability Exercise

The comparability exercise is intended to collect and evaluate relevant evidence showing that a manufacturing-process change has not adversely affected the product.

Q5E recognises common reasons for manufacturing changes, including:

Improvement of the manufacturing process.
Scale increase.
Improvement of product stability.
Changes made to comply with regulatory requirements.
Facility or equipment changes that can affect critical processing parameters.

The manufacturer evaluates quality attributes of the pre-change and post-change product and then determines whether additional nonclinical or clinical evidence is needed.

Comparable: Under Q5E, products are considered comparable when their quality attributes are highly similar and any differences are not expected to adversely affect safety or efficacy, including immunogenicity.

Scope of ICH Q5E

Q5E applies when all of the following conditions are present:

The product is a protein or polypeptide, derivative, or a product containing such material, including conjugates.
The product is produced from recombinant or non-recombinant cell-culture expression systems and can be highly purified and characterised using appropriate analytical procedures.
The change is made by one manufacturer, including a contract manufacturer arrangement, and direct comparison of pre-change and post-change product is possible.
The change occurs during development or after marketing authorisation.

The principles may also be relevant to certain products isolated from tissues or body fluids, but Q5E advises consultation with the appropriate regional regulatory authority to determine applicability.

General Principles of Comparability

A central Q5E principle is that comparability does not require pre-change and post-change products to be identical. The products should instead be highly similar, and existing product/process knowledge should be sufficiently predictive to show that any differences do not adversely affect safety or efficacy.

Analytical evidence firstQuality studies are the primary foundation of a comparability exercise.

Risk-based escalationNonclinical or clinical studies are added when analytical evidence is not sufficient to resolve uncertainty.

Totality of evidenceRoutine batch data, characterisation, process validation, in-process controls, stability, and historical knowledge are evaluated together.

Q5E also recognises that a manufacturing change can improve product quality. If the improvement is significant enough to imply a meaningful safety or efficacy benefit, the product may no longer fit the strict definition of “comparable,” even though the change itself may be acceptable. In such situations, consultation with the relevant authority is advised.

Comparability of Biotechnological/Biological Products

Possible Outcomes of a Q5E Comparability Exercise

Q5E describes several possible outcomes after evaluating pre-change and post-change quality data.

Outcome	Interpretation	Likely next step
Highly similar; no meaningful difference	No adverse effect on safety or efficacy is foreseen.	Product can be considered comparable based on quality data.
Highly similar, but analytical methods are insufficiently discriminating	Relevant differences might exist but cannot be adequately detected.	Add further characterisation and/or consider nonclinical or clinical studies.
Some quality differences are observed but can be scientifically justified	Existing knowledge supports the conclusion that the differences will not adversely affect safety or efficacy.	Product may still be considered comparable.
Differences raise unresolved safety/efficacy concerns	Additional analytical data are unlikely to resolve the concern.	Consider nonclinical and/or clinical bridging studies.
Differences are too significant	The products are not highly similar.	They are not considered comparable under Q5E.

How to Plan an ICH Q5E Comparability Exercise

The product should be evaluated at the manufacturing stage or stages most suitable for detecting the potential effect of the change. A change introduced during drug-substance manufacture can sometimes affect the final drug product, so evaluation may need to include intermediates, drug substance, and drug product.

The extent of the exercise depends on:

The process step where the change is introduced.
The potential effect on purity and physicochemical or biological properties.
The complexity and heterogeneity of the product.
The level of product and process knowledge.
The availability and capability of suitable analytical methods.
The relationship between quality attributes and safety/efficacy.

Data sources that can support the assessment

Physicochemical and biological characterisation.
Intermediate, drug-substance, and drug-product test results.
Manufacturing consistency batches.
Accelerated, stress, and real-time stability data where relevant.
Historical manufacturing data and trends.
Process development and validation/evaluation data.
In-process controls and critical control points.

Practical implementation context: In a modern pharmaceutical quality system, the Q5E comparability assessment is typically linked to formal change control, documented risk assessment, predefined comparability protocols where appropriate, investigation of unexpected differences, and CAPA when systemic issues are identified. These are practical quality-system integrations rather than additional requirements stated in Q5E.

Analytical Techniques for Q5E Comparability

The analytical test panel should be selected and optimised to maximise the ability to detect relevant changes in product quality attributes.

For complex products, Q5E recommends using more than one analytical procedure for the same attribute when the methods rely on different physicochemical or biological principles. This can increase confidence that subtle manufacturing-related differences will be detected.

Are existing methods still suitable?

A manufacturing change can create a new impurity profile or alter the way an existing attribute should be measured. Q5E therefore expects manufacturers to ask:

Is the existing method still appropriate for its intended use?
Does it have sufficient sensitivity, specificity, precision, and detection capability?
Does the changed process introduce impurities or attributes that the existing method cannot measure?
Should a new orthogonal method be added?

Validation expectations

Characterisation methods do not necessarily need to be fully validated, but they should be scientifically sound and provide reliable results. Methods used for routine release testing should be validated according to applicable ICH analytical-validation expectations.

For related reading, see the ICH Quality Guidelines hub.

Product Characterisation in Comparability Studies

Q5E points to ICH Q6B principles for characterising biotechnology and biological products. Relevant areas include:

Physicochemical properties.
Biological activity.
Immunochemical properties, when applicable.
Purity.
Product- and process-related impurities.
Contaminants.
Quantity.

A process change that can affect quality attributes generally warrants complete or limited but rationalised repetition of characterisation performed for the original marketing application. Additional characterisation may be needed when the post-change profile differs from material used in pivotal clinical studies, reference material, or marketed batches.

Physicochemical properties

Manufacturers should consider molecular heterogeneity and whether the post-change product retains its relevant higher-order structure. If direct structural data are not sufficiently informative, a relevant biological activity assay may help support the conclusion.

Biological activity

Biological assays can support product characterisation, routine batch testing, and sometimes provide a link to clinical activity. However, their variability can limit the ability to detect subtle differences.

For products with multiple functional activities, Q5E recommends considering a set of relevant functional assays that covers the range of biological functions.

Immunochemical properties

When immunochemical properties are relevant—for example, antibody or antibody-derived products—the specific properties should be compared before and after the change.

Purity, impurities, and contaminants

The analytical package should determine whether the purity profile has changed. New impurities should be identified and characterised when possible, and their potential effect on safety and efficacy should be assessed.

Contaminants should be avoided or controlled using suitable in-process acceptance criteria or action limits. Newly introduced contaminants require evaluation.

Key Q5E principle: Specifications alone are generally not sufficient to establish comparability because specifications confirm routine product quality but do not fully characterise the product.

Specifications After a Manufacturing Change

Post-change specifications should remain appropriate to assure product quality. Even when results meet existing acceptance criteria, values outside historical process trends can signal a meaningful product difference that deserves further investigation.

Q5E recognises that a test may need to be modified, added, or removed if the changed process alters the relevance of the existing specification. For example, eliminating bovine serum from the manufacturing process may remove the need for a related test.

Widening acceptance criteria is generally not appropriate without adequate justification. Conversely, new impurity species may justify additional tests or new acceptance limits.

Stability Studies in ICH Q5E Comparability

Stability can be a sensitive tool for detecting subtle changes that are not apparent in initial characterisation. Q5E specifically notes that small changes in processing, buffers, holding conditions, solvents, protease contamination, or container/closure interactions can alter the stability profile.

Real-time/real-temperature stability studies should therefore be initiated when the manufacturing change could affect product stability.

Accelerated and stress studies

Accelerated and stress stability studies are useful for comparing degradation pathways of pre-change and post-change material. They can:

Reveal differences not detected by routine characterisation.
Help establish degradation profiles.
Identify conditions that require additional manufacturing or storage controls.
Support selection of suitable storage conditions.

Q5E recommends consulting Q5C and the relevant ICH stability guideline when selecting conditions that provide meaningful pre-/post-change comparisons.

Manufacturing-Process Considerations

A changed manufacturing process should remain well controlled and should provide at least similar or more effective control of product quality compared with the original process.

The impact assessment should examine downstream consequences, including:

Acceptance criteria.
In-process specifications.
In-process tests.
Hold times.
Operating limits.
Validation or process evaluation.
Removal of product- and process-related impurities.

Re-evaluation and revalidation

Modified process steps should be re-evaluated or revalidated as appropriate. A simple change may only require focused work on the affected step if there is no evidence of downstream impact. Changes affecting multiple operations may require a broader validation package.

Examples of state-of-control evidence

Updated raw-material, source-material, starting-material, or reagent specifications.
Bioburden or viral-safety testing of post-change cell banks and cells at the limit of in vitro cell age.
Adventitious-agent clearance.
Removal of residual host-cell DNA and proteins.
Maintenance of purity.

Commercial-scale batches

For approved products, Q5E generally indicates use of commercial-scale data to support process changes and recommends analysing an appropriate number of post-change batches to demonstrate consistent process performance.

Side-by-side process description

The manufacturer should prepare a clear description of the change comparing the pre-change and post-change manufacturing process side by side, including changes in controls.

Demonstrating Comparability During Development

Manufacturing changes are expected during product development. The purpose of the comparability exercise is often to demonstrate that nonclinical or clinical data generated with the pre-change product can still be applied to the post-change product.

Early development

Comparability exercises are generally less extensive in early development because product/process knowledge and analytical capability are still evolving. If a change is made before nonclinical studies, comparability may not be a major issue because later nonclinical and clinical work will be conducted using the new process.

Late development

As development progresses, comparability studies should become more comprehensive. A late-stage process change introduced when no further clinical studies are planned should be evaluated with a level of rigour similar to that used for an approved product.

Analytical methods during development

Development-stage methods do not always need to be fully validated, but they should be scientifically sound, reliable, and reproducible. If analytical tools are too limited to establish comparability confidently, nonclinical or clinical bridging studies may be necessary.

When Are Nonclinical or Clinical Studies Needed?

Q5E allows comparability to be concluded from quality data alone when analytical evidence provides sufficient assurance. Additional nonclinical or clinical studies are appropriate when quality data do not resolve uncertainty.

Factors affecting the decision

Nature and magnitude of observed quality differences.
New or altered impurities.
Results of process validation and in-process testing.
Limitations of the available analytical methods.
Product complexity and higher-order structure.
Strength of the structure–activity relationship.
Mechanism of action.
Immunogenicity risk.
Therapeutic indication and patient population.
Route of administration and dosing regimen.
Therapeutic window and dose–response relationship.
Existing nonclinical and clinical experience.
PK/PD relationship, distribution, and clearance.

Types of bridging studies

Depending on the situation, Q5E identifies:

Pharmacokinetic studies.
Pharmacodynamic studies.
Combined PK/PD studies.
Clinical efficacy studies.
Specific safety studies.
Immunogenicity studies.
Pharmacovigilance studies.

Comparability bridging study: A nonclinical or clinical study that allows existing data from product made by the current process to be extrapolated to product made by the changed process.

Practical Example: Chromatography Process Change

Consider a monoclonal antibody manufacturer replacing one purification chromatography step with a new resin intended to improve throughput and impurity removal. A Q5E-aligned assessment would first define which quality attributes could plausibly be affected—such as host-cell proteins, aggregates, charge variants, residual DNA, glycan profile, and biological activity.

Pre-change and post-change material would be compared using sensitive and, where useful, orthogonal analytical methods. The new resin step would be evaluated for impurity clearance and process consistency. Stability studies could be added if the change has potential to alter degradation pathways. If differences are observed, the manufacturer would assess whether those differences are clinically meaningful using product/process knowledge, nonclinical information, and the established link between the affected attribute and safety or efficacy.

If analytical evidence provides sufficient assurance, no new clinical study may be needed. If an unresolved quality difference could affect immunogenicity or biological activity, a bridging study could become appropriate.

Example only: Q5E does not prescribe a fixed analytical panel or clinical-study requirement for a chromatography change. The depth of the exercise depends on the specific process step, product attributes, analytical capability, and the potential impact on safety and efficacy.

Practical Quality-System Integration

Q5E comparability activities should be implemented through a controlled pharmaceutical quality system. Manufacturing changes should be assessed through formal change control, supported by approved SOP procedures and appropriate cGMP controls.

Analytical datasets, batch histories, validation evidence, trend data, stability results, risk assessments, and comparability conclusions should remain complete and traceable in accordance with ALCOA+ principles. Where computerized systems are used, applicable 21 CFR requirements may also need to be considered.

Common ICH Q5E Comparability Mistakes

Assuming “comparable” means “identical.” Q5E allows justified differences when they do not adversely affect safety or efficacy.
Relying only on release specifications. Specifications are not a substitute for product characterisation.
Using analytical methods that cannot detect expected differences. The test panel should be tailored to the process change and product risk.
Ignoring stability. Some manufacturing changes reveal their effect only over time.
Looking only at the changed process step. Downstream impacts should also be evaluated.
Failing to examine historical trends. Gradual drift over a series of changes can be relevant.
Using early-development comparability standards for a late-stage or approved product. The exercise should become more comprehensive as development progresses.
Triggering clinical studies automatically. Q5E expects analytical evidence to be used first; clinical bridging is added when quality data are insufficient.

ICH Q5E Comparability Checklist

Describe the manufacturing change. Prepare a side-by-side pre-change and post-change process summary.
Identify potentially affected quality attributes. Include product- and process-related attributes and downstream consequences.
Define comparability criteria in advance. Use product/process knowledge, historical data, and relevant clinical understanding.
Select sensitive analytical methods. Use orthogonal methods where useful and confirm methods remain fit for purpose.
Compare appropriate manufacturing stages. Evaluate intermediates, drug substance, and/or drug product depending on where the effect could be detected.
Assess purity, impurities, biological activity, immunochemical properties, and structure. Add characterisation as needed for the specific change.
Evaluate stability. Use real-time and, where informative, accelerated/stress studies.
Re-evaluate process controls and validation. Confirm the post-change process remains in a state of control.
Determine whether quality data are sufficient. If uncertainty remains, consider nonclinical or clinical bridging.
Document the totality-of-evidence conclusion. Explain why observed similarities and differences support or do not support comparability.

Key Takeaways

ICH Q5E is the ICH guideline for comparability of biotechnology and biological products after manufacturing-process changes.
The current Step 4 version is dated 18 November 2004.
The primary goal is to show that the manufacturing change has not adversely affected product quality, safety, or efficacy.
Pre-change and post-change products do not need to be identical; they should be highly similar, and any differences should be scientifically understood.
Analytical and biological quality studies form the primary basis of the comparability assessment.
Release specifications alone are generally not enough to establish comparability.
Orthogonal analytical methods may be needed to detect subtle differences in complex products.
Stability studies can reveal process-change effects that initial characterisation may miss.
Post-change process controls should provide at least similar or more effective control of product quality.
Nonclinical or clinical bridging studies are added when quality evidence is not sufficient to establish comparability confidently.

Conclusion

ICH Q5E provides a practical, science-based framework for managing one of the most important lifecycle challenges in biotechnology manufacturing: changing the process without compromising the product.

A strong comparability exercise begins with a clear description of the change and a risk-based understanding of which quality attributes could be affected. It then combines sensitive analytical methods, product characterisation, process validation, trend data, stability, and manufacturing consistency evidence to determine whether pre-change and post-change material remain highly similar. When those data provide sufficient assurance, additional animal or human studies are not warranted. When uncertainty remains, Q5E provides the basis for escalating to nonclinical or clinical bridging. Integrated into a robust cGMP change-control system, this framework allows manufacturers to improve and evolve processes while protecting product quality, safety, and efficacy.

Frequently Asked Questions About ICH Q5E

1. What is ICH Q5E?

ICH Q5E is the harmonised ICH guideline for assessing comparability of biotechnology and biological products before and after manufacturing-process changes.

2. Does Q5E require pre-change and post-change products to be identical?

No. Q5E requires them to be highly similar, with any differences adequately understood and shown not to adversely affect safety or efficacy.

3. What types of products are covered by Q5E?

Q5E applies primarily to highly characterised proteins and polypeptides, their derivatives, and products containing them, produced using recombinant or non-recombinant cell-culture expression systems.

4. Can comparability be established using analytical studies alone?

Yes. If analytical and biological quality studies provide sufficient assurance of comparability, additional nonclinical or clinical studies are not warranted.

5. Are release specifications enough to demonstrate comparability?

No. Q5E states that specifications alone are generally inadequate because they are designed for routine quality control rather than comprehensive product characterisation.

6. Why are stability studies important in Q5E?

Stability studies can detect subtle differences in degradation pathways or product behaviour that may not be visible during initial characterisation.

7. When should new analytical methods be added?

New methods may be needed when the process change introduces a new impurity, changes an existing quality attribute, or creates differences that existing analytical methods cannot adequately detect.

8. Does Q5E apply during product development?

Yes. Comparability exercises are used during development to support continued use of pre-change nonclinical or clinical data, and they generally become more comprehensive as development progresses.

9. When are clinical bridging studies needed?

Clinical or nonclinical bridging is considered when quality data are insufficient to establish comparability or when observed differences could plausibly affect safety, efficacy, pharmacokinetics, pharmacodynamics, or immunogenicity.

10. What is a comparability bridging study?

It is a nonclinical or clinical study used to support extrapolation of existing data from product made by the current process to product made by the changed process.

Editorial source note: This article is an original explanatory adaptation of ICH Q5E, Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process. Practical quality-system comments are included to improve usability and are clearly distinguished from source-derived requirements. This article does not replace the official ICH guideline, an approved dossier, regional regulatory requirements, or product-specific comparability advice.